Publication
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Neoplasmcivic_curation1.00
- drugAtezolizumabcivic_curation1.00
- drugNivolumabcivic_curation1.00
- drugPembrolizumabcivic_curation1.00
- geneDNMT3Acivic_curation1.00
- variantDNMT3A Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28351930
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| DNMT3A Mutation1 | ||||||||
| Atezolizumab + Nivolumab + PembrolizumabSubstitutes | Malignant NeoplasmALIAS | Predictive | B | Supports Resistance | 2 | accepted | EID2926A subset of patients receiving PD1/PD-L1 inhibition appear to be "hyper-progressors," with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current st… (full text at CIViC) PMID 28351930 · Kato et al., 2017 · Open in CIViC | civic |
| MDM2 Amplification1 | ||||||||
| Ipilimumab + Nivolumab + PembrolizumabSubstitutes | Malignant NeoplasmALIAS | Predictive | B | Supports Adverse Response | 3 | submitted | EID2916A study to investigate potential genomic markers associated with "hyper-progression" in patients treated with PD1/PD-L1 inhibition. Amongt 155 patients, TTF (time to treatment failure) <2 months was s… (full text at CIViC) PMID 28351930 · Kato et al., 2017 · Open in CIViC | civic |
| MDM4 Amplification1 | ||||||||
| Atezolizumab + Nivolumab + PembrolizumabSubstitutes | Malignant NeoplasmALIAS | Predictive | B | Supports Adverse Response | 3 | submitted | EID2925A subset of patients receiving PD1/PD-L1 inhibition appear to be "hyper-progressors," with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current st… (full text at CIViC) PMID 28351930 · Kato et al., 2017 · Open in CIViC | civic |
| MDM4 EXPRESSION1 | ||||||||
| Atezolizumab + Nivolumab + PembrolizumabSubstitutes | Malignant NeoplasmALIAS | Predictive | B | Supports Adverse Response | 3 | submitted | EID2917A subset of patients receiving PD1/PD-L1 inhibition appear to be "hyper-progressors," with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current st… (full text at CIViC) PMID 28351930 · Kato et al., 2017 · Open in CIViC | civic |